MétaCan
Menu
Back to cohort
Record W4389034954 · doi:10.1093/ofid/ofad500.456

386. Participant Reflections on Their Experiences Participating in Phase 1 and 2 Inpatient Vaccine Trials and Human Challenge Studies

2023· article· en· W4389034954 on OpenAlexaffabout
Bettina Wunderlich, Kathryn Chang, Lawrence H. Moulton, Nancy Kass, Ruth A. Karron, Kawsar R. Talaat

Bibliographic record

VenueOpen Forum Infectious Diseases · 2023
Typearticle
Languageen
FieldMedicine
TopicEthics in Clinical Research
Canadian institutionsPfizer (Canada)
FundersSanofiPfizer
KeywordsMedicineClinical trialFamily medicinePoisson regressionDemographyEnvironmental healthInternal medicinePopulation

Abstract

fetched live from OpenAlex

Abstract Background Volunteers are critical for the success of clinical trials but there is still debate on the ethics surrounding recruitment and enrollment of healthy human subjects who are paid for their participation in such research. This study seeks to examine the experiences and perceptions of risks and benefits of participants in early-phase inpatient studies to gain greater insight into how they feel about participating. Methods An interviewer-administered survey was conducted with 152 healthy volunteers who participated in at least one Phase 1 or 2 inpatient vaccine or challenge clinical trial at the Johns Hopkins Center for Immunization Research, during the years of 2010-2020. Participant characteristics, study experiences, and perceived risks were analyzed. Poisson regression with robust variance was used to examine factors associated with perception of risk before and after participation. Results Most participants who completed the survey were male (62%) and Black or African American (78%). 53% attained at most a high school degree and 42% had an income below $18,500 a year. Compensation was the primary factor for joining a study for 68% of participants; 35% of them relied on clinical trials as a major part of their income. Nevertheless, 32% reported they declined to participate in at least one study and 63% reported that they ask about the side effects before joining a new study. Over 90% of participants agreed or strongly agreed that they enjoyed participating, wanted to participate, and were glad they joined the study. There was a significant reduction in the perceived risk of study participation after study completion compared to perceived risk before joining the study, where before the study 46% thought it was “Not at all risky” compared to 73% afterwards. Conclusion Most participants in our early-phase inpatient studies are males of lower income and compensation was the primary motivator for joining. However, side effects do factor in their decision whether to join. The majority of participants indicated that they were glad they joined the study. Despite the studies having risks and expected side effects, there was also a significant decline in perception of risks related to the study following participation, which implies participants feel safer than they anticipated feeling. Disclosures Lawrence Moulton, PhD, Pfizer Canada ULC: Employee Kawsar R. Talaat, MD, Intralytix: Advisor/Consultant|Merck: Advisor/Consultant|NIAID: DSMB|Pfizer: Grant/Research Support|Pfizer: Pfizer contract with institution|Sanofi: Grant/Research Support|Takeda: Advisor/Consultant

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.021
metaresearch head score (Gemma)0.034
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Evaluation · Consensus signal: none
Study designCandidate signal: Qualitative · Consensus signal: Qualitative
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.979
Threshold uncertainty score0.112

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0210.034
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0050.002
Scholarly communication0.0030.002
Open science0.0010.004
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.812
GPT teacher head0.684
Teacher spread0.127 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designQualitative
DomainEvaluation
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicEthics in Clinical ResearchFrench-language works237,207